Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Author Correction: Specific oncogene activation of the cell of origin in mucosal melanoma.
Journal: Nature communications
Published: August 20, 2026
Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response.
Journal: Pigment cell & melanoma research
Published: April 20, 2025
Recurrent ZC3H18 mutations stabilize oncogenic endogenous retroviral RNA.
Journal: Cell reports
Published: January 29, 2025
Recurrent oncogenic ZC3H18 mutations stabilize endogenous retroviral RNA.
Journal: bioRxiv : the preprint server for biology
Published: January 27, 2025
A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma.
Journal: Cell
Published: December 16, 2024
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.
Journal: Journal for immunotherapy of cancer
Published: August 06, 2024
Specific oncogene activation of the cell of origin in mucosal melanoma.
Journal: Nature communications
Published: June 05, 2024
Specific oncogene activation of the cell of origin in mucosal melanoma.
Journal: bioRxiv : the preprint server for biology
Published: May 07, 2024
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.
Journal: The oncologist
Published: March 06, 2024
Oncogenic CDK13 mutations impede nuclear RNA surveillance.
Journal: Science (New York, N.Y.)
Published: April 20, 2023
Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy.
Journal: World neurosurgery
Published: April 01, 2020
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.
Journal: Cancer discovery
Published: May 07, 2019
Showing 1-12 of 12
Last Updated: 09/26/2026